Researchers are increasingly turning to modular mechanistic models to unlock greater efficiency and robustness in mRNA manufacturing, offering a more flexible way to optimize in vitro transcription (IVT) while reducing costly experimental work. According to Wei Xie, PhD, associate professor of mechanical and industrial engineering at Northeastern University, and her colleagues, modular approaches can increase productivity and product quality.
“A modular modeling approach simplifies the complex IVT reaction network by dividing it into discrete, reusable, mechanistically defined steps,” Xie said. “This structure improves mechanistic understanding by clarifying how each step impacts key quality attributes, including yield, capping efficiency, and transcript integrity.”
Rather than relying on a single monolithic model, the framework separates IVT into individual components, such as initiation, elongation, and termination, as well as parallel processes including mRNA degradation and precipitation. Each module can be independently calibrated, validated, and refined as new experimental data become available, allowing researchers to continuously improve predictive performance without rebuilding the entire model.
The modular architecture also lends itself to the evolving nature of mRNA therapeutics. Because the framework mirrors the modular structure of nucleic-acid sequences, it can be rapidly adapted for new constructs, accelerating process development for emerging vaccines and therapeutic candidates while minimizing redevelopment effort. Beyond improving process understanding, the model provides a powerful diagnostic platform for identifying production bottlenecks that constrain yield, productivity, or product quality.
The framework combines Shapley value-based sensitivity analysis, residual analysis, and simulated reaction trajectories to pinpoint limiting process variables. Sensitivity analysis identifies parameters with the greatest influence on performance, while comparisons between predicted and experimental results reveal missing mechanisms or model deficiencies. Simulated reaction profiles can also highlight issues such as nucleotide depletion or suboptimal magnesium-to-nucleotide ratios before they become significant manufacturing challenges.
“Together, these tools provide a data-driven, mechanistic approach to quickly diagnose constraints and guide targeted process optimization,” Xie explains.
The approach also offers significant advantages during scale-up, one of the most challenging phases of bioprocess development. Because the model is grounded in fundamental molecular reactions and biochemical mechanisms rather than empirical correlations, it maintains predictive capability across different manufacturing scales and can be readily applied to new mRNA sequences, all without extensive redevelopment.
Xie says the framework supports predictive design of scale-dependent control strategies, including dynamic pH regulation and fed-batch nucleotide feeding schemes, helping manufacturers reduce development timelines while improving process robustness during technology transfer.
“A key advantage of the modular architecture is its flexibility and interoperability” Xie says. “New enzymes, reagents, or process steps can be incorporated by simply updating or adding the relevant module, without recalibrating the entire model. The framework’s ability to accommodate heterogeneous datasets generated under varying process conditions further supports rapid evaluation of manufacturing innovations while maintaining model consistency.
Perhaps the greatest impact of Xie’s approach lies in advancing quality-by-design (QbD). Acting as an in silico development platform, the modular model enables researchers to evaluate process variables before entering the laboratory. Coupled with digital twin-based Bayesian optimization, the platform narrows the experimental search space, reducing trial-and-error studies while conserving expensive reagents, such as T7 RNA polymerase.
As mRNA pipelines continue to expand beyond vaccines into broader therapeutic applications, modular mechanistic modeling is emerging as a valuable digital bioprocessing tool, enabling manufacturers to accelerate development, strengthen process understanding, and deliver more consistent product quality with fewer experimental resources.
The post Modular Modeling Drives Smarter mRNA Manufacturing appeared first on GEN – Genetic Engineering and Biotechnology News.
